Esophageal Squamous Cell Carcinoma
Showing 1 - 25 of >10,000
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 30, 2023
Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Recruiting
- Esophageal Squamous Cell Carcinoma
-
Shijiazhuang, Hebei, ChinaDepartment of Thoracic Surgery, Fourth Hospital of Hebei Medical
Oct 25, 2023
Advanced Esophageal Squamous Carcinoma With Oligometastases Trial (simultaneous with radiotherapy, synchronous with
Not yet recruiting
- Advanced Esophageal Squamous Carcinoma With Oligometastases
- simultaneous with radiotherapy
- synchronous with radiotherapy
- (no location specified)
Nov 16, 2023
Metastatic Esophageal Squamous Cell Carcinoma Trial in Qingdao (TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1
Recruiting
- Metastatic Esophageal Squamous Cell Carcinoma
- TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors(Sintilimab)
-
Qingdao, Shandong, China
- +1 more
Nov 13, 2023
Esophageal Squamous Cell Carcinoma Trial in Wuhan (no intervention)
Recruiting
- Esophageal Squamous Cell Carcinoma
- no intervention
-
Wuhan, Hubei, ChinaRenmin hosptial of Wuhan University
Jul 29, 2023
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Tirelizumab, Nab paclitaxel, Carboplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Tirelizumab
- +3 more
-
Shanghai, Shanghai, ChinaRuijin hospital, Shanghai jiaotong university school of medicine
Nov 6, 2023
Esophageal Squamous Cell Carcinoma Trial (Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
- (no location specified)
Aug 17, 2023
Esophageal Squamous Cell Carcinoma Trial (LY01015, Fluorouracil, Cisplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- LY01015
- +3 more
- (no location specified)
Aug 28, 2023
Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- LDRT+CFRT
- +2 more
-
Shanghai, China
- +1 more
Aug 3, 2023
Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- PD-1 Inhibitors
-
Zhengzhou, Henan, ChinaFeng Wang
Oct 9, 2023
Esophageal Squamous Cell Carcinoma Trial in Shantou (Tislelizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
-
Shantou, Guangdong, ChinaCancer Hospital of Shantou University Medical College
Aug 2, 2023
Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Chengdu (Camrelizumab, Dalpiciclib 100mg,
Recruiting
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Camrelizumab
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Oct 25, 2023
Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou
Not yet recruiting
- Minimal Residual Disease
- Esophageal Squamous Cell Carcinoma
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Jun 10, 2023
Esophageal Squamous Cell Carcinoma Trial in Nanjing (Carrelizumab, Paclitaxel injection, Cisplatin)
Enrolling by invitation
- Esophageal Squamous Cell Carcinoma
- Carrelizumab
- +3 more
-
Nanjing, ChinaThe First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023
Esophageal Cancer Trial in Wuhan
Recruiting
- Esophageal Cancer
-
Wuhan, Hubei, ChinaRenmin hosptial of Wuhan University
Jun 7, 2023
Esophageal Squamous Cell Carcinoma Trial in Wuhan (Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Intensity-modulated radiotherapy (IMRT)
- +3 more
-
Wuhan, Hubei, ChinaRenmin hosptial of Wuhan University
Jun 16, 2023
Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial (cadonilimab+chemo)
Not yet recruiting
- Resectable Esophageal Squamous Cell Carcinoma
- Neoadjuvant Therapy
- (no location specified)
Apr 18, 2023
Esophageal Squamous Cell Carcinoma Trial (XH-30002 capsule, Afatiinb tablet)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- XH-30002 capsule
- Afatiinb tablet
- (no location specified)
Jun 25, 2023
The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC Trial in Hanzhou (Cadonilimab Combined Albumin-paclitaxel,
Recruiting
- The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
- Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
-
Hanzhou, Zhejiang, ChinaLulu Liu
Jul 14, 2023
NLR and Its Association With Efficacy of Immunochemotherapy in
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Nov 10, 2023
Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Cadonilimab combined Anlotinib
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy Trial in Shanghai (Tislelizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
-
Shanghai, Shanghai, ChinaShanghai chest hospital
Sep 24, 2023
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (Radiotherapy, Toripalimab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Radiotherapy
- Toripalimab
- (no location specified)
Mar 17, 2023
Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- AK104, nab-paclitaxel, carboplatin
-
Anyang, Henan, China
- +1 more
Jun 1, 2023